LCH
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH (NCT05997602) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2023-09-28 |
| The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation (NCT05092815) | Shanghai Henlius Biotech | 2021-12-06 |
Track LCH automatically
Every clearance here is in the API, with alerts when new ones post.